SCHEMBL3961898

SCHEMBL3961898

C[C@@H]1CN(CCCN2C(=O)c3ccccc3C2=O)C[C@H](C)N1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.59
KDM4E B2RXH2 2/20 0.59
TDP1 Q9NUW8 1/20 0.59
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
SIGMAR1 Q99720 2/20 0.56
HTR2B P41595 2/20 0.56
TP53 P04637 1/20 0.56
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2D6 P10635 1/20 0.56
CYP2C9 P11712 1/20 0.56
ALOX15 P16050 1/20 0.56
TSHR P16473 1/20 0.56
HTR2A P28223 1/20 0.56
HTR2C P28335 1/20 0.56
MAPK1 P28482 1/20 0.56
CYP2C19 P33261 1/20 0.56
HTT P42858 1/20 0.56
SCARB1 Q8WTV0 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3962101 0.84 KDM4E (0.60) ALDH1A1KDM4ETDP1SIGMAR1HTR2B
SCHEMBL2245540 0.79 ALDH1A1 (0.55) ALDH1A1KDM4ETDP1MEN1KMT2A
SCHEMBL13469510 0.77 HTR1A (0.79) MAOBHTR1ADRD3DRD2
SCHEMBL7986506 0.77 KDM4E (0.56) ALDH1A1KDM4ETDP1HTR1A
SCHEMBL7986503 0.77 KDM4E (0.56) ALDH1A1KDM4ETDP1HTR1A
SCHEMBL4351612 0.77 TDP1 (0.66) TDP1MEN1KMT2ACYP1A2CYP2D6
SCHEMBL3886553 0.77 HTR1A (0.58) ALDH1A1KDM4ETDP1HTR2BMAOB
SCHEMBL3893010 0.77 HTR1A (0.58) ALDH1A1KDM4ETDP1HTR2BMAOB
SCHEMBL29574643 0.77 KDM4E (0.59) ALDH1A1KDM4ETDP1HTR2BMAOB
SCHEMBL1532232 0.75 MAOB (0.73) HTR2AMAOBHTR1ADRD3DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1989200-B1 [4-(BENZO[B]THIOPHEN-2-YL)-PYRIMIDIN-2-YL]-AMINE DERIVATIVES AS IKK-BETA INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES LILLY CO ELI (US) 2009-07-29 EP disclosed
US-7547691-B2 [4-(Benzo[B]thiophen-2-yl) Pyrimidin-2-yl]-amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseases ELI LILLY AND COMPANY (US) 2009-06-16 US disclosed
US-20080306082-A1 [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases ELI LILLY AND COMPANY 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306082-A1 [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases NFKBIA, IKBKB, IKBKG ALDH1A1 2074/4885KDM4E 436/4885TDP1 810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.